Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza

Influenza and other Respiratory Viruses

Volumn 6, Issue 3, 2012, Pages 176-187

  Vodeiko, Galina M ^a   Weir, Jerry P ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Pandemic influenza; Single radial immunodiffusion assay; Vaccine potency

Indexed keywords

ANTISERUM; INFLUENZA VACCINE; INFLUENZA VIRUS A H5N1 VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENCY; DRUG STABILITY; IMMUNODIFFUSION; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CROSS REACTIONS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; SHEEP; SPECIES SPECIFICITY; VACCINES, INACTIVATED;

EID: 84859745863     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2011.00285.x     Document Type: Article

References (33)

1. Schild GC, Henry-Aymard M, Pereira HG. A quantitative, single-radial-diffusion test for immunological studies with influenza virus. J Gen Virol 1972; 16:231-236.
2. Schild GC, Smith JW, Cretescu L, Newman RW, Wood JM. Strain-specificity of antibody to haemagglutinin following inactivated A/port chalmers/1/73 vaccine in man: evidence for a paradoxical strain-specific antibody response. Dev Biol Stand 1977; 39:273-281.
3. Mostow SR, Schild GC, Dowdle WR, Wood RJ. Application of the single radial diffusion test for assay of antibody to influenza type A viruses. J Clin Microbiol 1975; 2:531-540.
4. Wood JM, Schild GC, Newman RW, Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977; 5:237-247.
5. Williams MS, Mayner RE, Daniel NJ et al. New developments in the measurement of the hemagglutinin content of influenza virus vaccines by single-radial-immunodiffusion. J Biol Stand 1980; 8:289-296.
6. Williams MS. Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol 1993; 4:253-262.
7. Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis 1983; 5:737-747.
8. La Montagne JR, Noble GR, Quinnan GV et al. Summary of clinical trials of inactivated influenza vaccine - 1978. Rev Infect Dis 1983; 5:723-736.
9. Quinnan GV, Schooley R, Dolin R, Ennis FA, Gross P, Gwaltney JM. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev Infect Dis 1983; 5:748-757.
10. Wright PF, Cherry JD, Foy HM et al. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety. Rev Infect Dis 1983; 5:758-764.
11. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767-777.
12. Kapteyn JC, Porre AM, de Rond EJ et al. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009; 27:1468-1477.
13. Garcia-Canas V, Lorbetskie B, Bertrand D, Cyr TD, Girard M. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Anal Chem 2007; 79:3164-3172.
14. Williams TL, Luna L, Guo Z et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008; 26:2510-2520.
15. Nilsson CE, Abbas S, Bennemo M, Larsson A, Hamalainen MD, Frostell-Karlsson A. A novel assay for influenza virus quantification using surface plasmon resonance. Vaccine 2010; 28:759-766.
16. Wood JM. Developing vaccines against pandemic influenza. Philos Trans R Soc Lond B Biol Sci 2001; 356:1953-1960.
17. US Department of Health and Human Services. HHS Pandemic Influenza Plan. Washington, DC, 2005. Available at (Accessed 19 April 2011).
18. US Department of Health and Human Services. HHS Pandemic Planning Update, a Report from Secretary Michael O. Leavitt. Washington DC, 2006. Available at (Accessed 19 April 2011).
19. US Homeland Security Council. National Strategy for Pandemic Influenza. Washington DC, 2005. Available at (Accessed 19 April 2011).
20. US Homeland Security Council. Implementation Plan for the National Strategy for Pandemic Influenza. Washington DC, 2006. Available at (Accessed 19 April 2011).
21. Webby RJ, Perez DR, Coleman JS et al. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004; 363:1099-1103.
22. WHO. WHO Expert Committee on Biological Standardization, Thirtieth report. Geneva: World Health Organization, 1979, Annex 3 (WHO Technical Report Series, No. 638).
23. WHO. Recommendations for production and quality control of inactivated influenza vaccines. In: WHO Expert Committee on Biological Standardization. Fifty-fourth report. Geneva: World Health Organization, 2005, Annex 3 (WHO Technical Report Series, No. 927).
24. Schmeisser F, Vodeiko GM, Lugovtsev VY, Stout RR, Weir JP. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 2010; 28:2442-2449.
25. Palmer DF, Coleman MT, Dowdle WR, Schild GC. Advanced Laboratory Techniques for Influenza Diagnosis. Washington, D.C.: U.S. Department of Health Education and Welfare, 1975.
26. WHO. Continuing Progress Towards a Unified Nomenclature System for the Highly Pathogenic H5N1 Avian Influenza Viruses. Geneva: World health Organization, 2009. Available at (Accessed 22 August 2011).
27. Rudneva IA, Kushch AA, Masalova OV et al. Antigenic epitopes in the hemagglutinin of Qinghai-type influenza H5N1 virus. Viral Immunol 2010; 23:181-187.
28. Wu WL, Chen Y, Wang P et al. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J Virol 2008; 82:1798-1807.
29. Kaverin NV, Rudneva IA, Ilyushina NA et al. Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol 2002; 83:2497-2505.
30. Kaverin NV, Rudneva IA, Govorkova EA et al. Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies. J Virol 2007; 81:12911-12917.
31. Schuchat A, Bell BP, Redd SC. The science behind preparing and responding to pandemic influenza: the lessons and limits of science. Clin Infect Dis 2011; 52(Suppl 1):S8-S12.
32. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650-658.
33. Nabel GJ, Wei CJ, Ledgerwood JE. Vaccinate for the next H2N2 pandemic now. Nature 2011; 471:157-158.